Literature DB >> 12547702

Increased furin activity enhances the malignant phenotype of human head and neck cancer cells.

Daniel E Bassi1, Haleh Mahloogi, Ricardo Lopez De Cicco, Andres Klein-Szanto.   

Abstract

Many proteins are synthesized as inactive proforms requiring a proteolytic processing to render them active. A variety of proteases catalyze these cleavage reactions. Proprotein convertases are a family of serine proteases capable of activating substrates that will subsequently intervene in extracellular matrix (ECM) degradation, cell growth, differentiation and viral pathogenesis. Furin, the prototype of this family, has been implicated in many physiological and pathological processes. Some of its substrates such as TGF-beta, MT-MMP's, and IGFR-1 have been identified. Overexpression of furin has been observed in several human tumors. In this report we demonstrate that overexpression of furin causes a significant increase in the invasive potential of human tumor cells of low and moderate aggressive potential in vitro and in vivo. SCC12 and SCC15 were transfected with furin cDNA, resulting in efficient processing of furin substrates. An in vivo invasion assay showed enhancement of invasive ability. Inhibition of furin activity with the synthetic inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl-ketone, CMK, showed a significant decrease in both processing and in vitro invasiveness. A moderate enhancement in proliferation rate was observed when cells were transfected with furin. CMK treatment resulted in a marked reduction of this effect. Tumors obtained after subcutaneous (s.c.) inoculation of furin-overexpressing cells were larger and developed earlier than the controls. Furin overexpression caused an imbalance in the activation of invasion and proliferation-related substrates leading to the acquisition of an advanced malignant phenotype. In addition, inhibition of furin activity decreases substrate activation, proliferation rate, and invasive potential of cancer cells, suggesting that furin is a potentially useful target for therapeutics.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12547702      PMCID: PMC1851171          DOI: 10.1016/S0002-9440(10)63838-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

1.  Processing of wild-type and mutant proinsulin-like growth factor-IA by subtilisin-related proprotein convertases.

Authors:  S J Duguay; W M Milewski; B D Young; K Nakayama; D F Steiner
Journal:  J Biol Chem       Date:  1997-03-07       Impact factor: 5.157

2.  Pro-protein convertase gene expression in human breast cancer.

Authors:  M Cheng; P H Watson; J A Paterson; N Seidah; M Chrétien; R P Shiu
Journal:  Int J Cancer       Date:  1997-06-11       Impact factor: 7.396

Review 3.  Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins.

Authors:  K Nakayama
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

4.  Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions.

Authors:  A M Khatib; G Siegfried; A Prat; J Luis; M Chrétien; P Metrakos; N G Seidah
Journal:  J Biol Chem       Date:  2001-06-11       Impact factor: 5.157

Review 5.  Bi-cycling the furin pathway: from TGN localization to pathogen activation and embryogenesis.

Authors:  S S Molloy; E D Anderson; F Jean; G Thomas
Journal:  Trends Cell Biol       Date:  1999-01       Impact factor: 20.808

6.  Type IV collagen induces matrix metalloproteinase 2 activation in HT1080 fibrosarcoma cells.

Authors:  E Maquoi; F Frankenne; A Noël; H W Krell; F Grams; J M Foidart
Journal:  Exp Cell Res       Date:  2000-12-15       Impact factor: 3.905

Review 7.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

8.  Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor.

Authors:  E Maquoi; A Noël; F Frankenne; H Angliker; G Murphy; J M Foidart
Journal:  FEBS Lett       Date:  1998-03-13       Impact factor: 4.124

9.  Insulin-like growth factors are mitogenic for human keratinocytes and a squamous cell carcinoma.

Authors:  E K Neely; V B Morhenn; R L Hintz; D M Wilson; R G Rosenfeld
Journal:  J Invest Dermatol       Date:  1991-01       Impact factor: 8.551

10.  Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours.

Authors:  M Mbikay; F Sirois; J Yao; N G Seidah; M Chrétien
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  36 in total

1.  Molecular Validation of PACE4 as a Target in Prostate Cancer.

Authors:  François D'Anjou; Sophie Routhier; Jean-Pierre Perreault; Alain Latil; David Bonnel; Isabelle Fournier; Michel Salzet; Robert Day
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF.

Authors:  Meng Tong; Brandon Lloyd; Ping Pei; Susan R Mallery
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

3.  A genome-wide expression quantitative trait loci analysis of proprotein convertase subtilisin/kexin enzymes identifies a novel regulatory gene variant for FURIN expression and blood pressure.

Authors:  Hannu Turpeinen; Ilkka Seppälä; Leo-Pekka Lyytikäinen; Emma Raitoharju; Nina Hutri-Kähönen; Mari Levula; Niku Oksala; Melanie Waldenberger; Norman Klopp; Thomas Illig; Nina Mononen; Reijo Laaksonen; Olli Raitakari; Mika Kähönen; Terho Lehtimäki; Marko Pesu
Journal:  Hum Genet       Date:  2015-03-27       Impact factor: 4.132

4.  Enhanced aggressiveness of benzopyrene-induced squamous carcinomas in transgenic mice overexpressing the proprotein convertase PACE4 (PCSK6).

Authors:  Daniel E Bassi; Jonathan Cenna; Jirong Zhang; Edna Cukierman; Andres J Klein-Szanto
Journal:  Mol Carcinog       Date:  2014-05-21       Impact factor: 4.784

5.  Propeptides are sufficient to regulate organelle-specific pH-dependent activation of furin and proprotein convertase 1/3.

Authors:  Stephanie L Dillon; Danielle M Williamson; Johannes Elferich; David Radler; Rajendra Joshi; Gary Thomas; Ujwal Shinde
Journal:  J Mol Biol       Date:  2012-06-25       Impact factor: 5.469

Review 6.  Endo/exo-proteolysis in neoplastic progression and metastasis.

Authors:  Abdel-Majid Khatib; Daniel Bassi; Geraldine Siegfried; Andres J P Klein-Szanto; L'Houcine Ouafik
Journal:  J Mol Med (Berl)       Date:  2005-08-26       Impact factor: 4.599

7.  TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma.

Authors:  Jieqiong Liu; Shan Liao; Benjamin Diop-Frimpong; Wei Chen; Shom Goel; Kamila Naxerova; Marek Ancukiewicz; Yves Boucher; Rakesh K Jain; Lei Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-20       Impact factor: 11.205

8.  A femtomol range FRET biosensor reports exceedingly low levels of cell surface furin: implications for the processing of anthrax protective antigen.

Authors:  Katarzyna Gawlik; Albert G Remacle; Sergey A Shiryaev; Vladislav S Golubkov; Mingxing Ouyang; Yingxiao Wang; Alex Y Strongin
Journal:  PLoS One       Date:  2010-06-24       Impact factor: 3.240

9.  Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse model.

Authors:  Katarina Hajdin; Valentina D'Alessandro; Felix K Niggli; Beat W Schäfer; Michele Bernasconi
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

10.  Enhanced UV-induced skin carcinogenesis in transgenic mice overexpressing proprotein convertases.

Authors:  Jian Fu; Daniel E Bassi; Jirong Zhang; Tianyu Li; Kathy Q Cai; Courtney Lyons Testa; Emmanuelle Nicolas; Andres J Klein-Szanto
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.